Search Theodore F. reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.
Ciccio John reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.
Acevedo Christopher P. reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 100,000 shares. Following the reported transactions, holdings were 100,000 shares.
PETIT ROBERT reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 100,000 shares. Following the reported transactions, holdings were 100,000 shares.
Romness Paul A. reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 1,000,000 shares. Following the reported transactions, holdings were 1,000,000 shares.
Jarry Olivier Roger reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.
Galzahr Karim reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.
OS Therapies President and CEO Paul A. Romness reported an amended insider transaction reflecting a grant of 1,000,000 stock options on October 21, 2025. The options have an exercise price of $1.8 per share, are fully vested on the one-year anniversary of the grant date, and expire on October 21, 2035, assuming continued employment on the vesting date. Following this award, Romness beneficially owned 2,473,000 shares of common stock directly. The amendment corrects an earlier filing that had misreported the number of shares underlying this stock option grant.
OS Therapies Incorporated updated investors on its ongoing warrant inducement transaction. The company previously entered into agreements with fewer than 10 accredited investors holding existing warrants to purchase up to 5,382,148 shares of common stock. These investors were offered the opportunity to exercise, or pre-fund the exercise of, their existing warrants for cash at a reduced exercise price of $1.40 per share, or $1.399 per share in the case of pre-funding. In return, the company agreed to issue new common stock purchase warrants to purchase up to an aggregate of 5,382,148 shares at an exercise price of $1.40 per share, subject to adjustment. The company has now extended the inducement offering period from its original expiration at 11:59 p.m. Eastern time on February 10, 2026, to 11:59 p.m. Eastern time on March 2, 2026, giving holders additional time to participate.
OS Therapies Incorporated entered into warrant inducement offer letters with fewer than 10 accredited investors holding existing warrants to purchase up to 5,382,148 shares of common stock. The investors agreed to exercise these existing warrants for cash at a reduced exercise price of $1.40 per share, and in return the company will issue new warrants to purchase up to 5,382,148 additional shares at the same exercise price, exercisable immediately for five years.
The company engaged an SEC-registered broker-dealer as exclusive solicitation agent and expects aggregate gross proceeds of approximately $7.5 million, before an 8.0% cash fee to the agent and up to $25,000 of expenses. OS Therapies plans to use the net proceeds to support U.S. and international regulatory and pre-commercial efforts for OST-HER2 in osteosarcoma, to help fund spinoff preparations for its OS Animal Health subsidiary, and for general corporate purposes.
The new warrants include beneficial ownership caps of 4.99% or, at the holder’s election, 9.99%, a potential forced exercise feature if the stock trades at or above 300% of the exercise price for 20 consecutive trading days, and a cashless exercise option if a resale registration statement is not effective. The company agreed to file a resale registration statement for shares issuable upon exercise of the new warrants within 30 days of closing.